More articles from Theranostics

You have access
A 2022 INTERNATIONAL SURVEY ON THE STATUS OF PROSTATE CANCER THERANOSTICS
Thomas Beyer, Johannes Czernin, Lutz S Freudenberg, Frederik Giesel, Marcus Hacker, Rodney J. Hicks and Bernd Krause

Journal of Nuclear Medicine August 11, 2022, jnumed.122.264298; DOI: https://doi.org/10.2967/jnumed.122.264298
You have access
Survival Outcomes in Metastatic Gastroenteropancreatic Neuroendocrine Tumor Patients receiving Concomitant ²²⁵Ac-DOTATATE Targeted Alpha Therapy and Capecitabine: A Real-world Scenario Management Based Long-term Outcome Study
Sanjana Ballal, Madhav Prasad Yadav, Madhavi Tripathi, Ranjit Kumar Sahoo and Chandrasekhar Bal

Journal of Nuclear Medicine July 21, 2022, jnumed.122.264043; DOI: https://doi.org/10.2967/jnumed.122.264043
You have access
The prognostic value of post-treatment PSMA and FDG PET/CT in metastatic, castration-resistant prostate cancer treated with ¹⁷⁷LuPSMA-617 and NOX66 in a phase I/II trial (LuPIN).
Sarennya Pathmanandavel, Megan Crumbaker, Andrew Nguyen, Andrew On Wah Yam, Peter Wilson, Remy Niman, Maria Ayers, Shikha Sharma, Peter Eu, Andrew J Martin, Martin R Stockler, Anthony M Joshua and Louise Emmett

Journal of Nuclear Medicine June 23, 2022, jnumed.122.264104; DOI: https://doi.org/10.2967/jnumed.122.264104
You have access
A novel dimeric FAP-targeting small molecule-radio conjugate with high and prolonged tumour uptake
Andrea Galbiati, Aureliano Zana, Matilde Bocci, Jacopo Millul, Abdullah Elsayed, Jacqueline Mock, Dario Neri and Samuele Cazzamalli

Journal of Nuclear Medicine May 19, 2022, jnumed.122.264036; DOI: https://doi.org/10.2967/jnumed.122.264036
You have access
⁸⁹Zr-3,2-HOPO-mesothelin antibody PET imaging reflects tumor uptake of mesothelin targeted ²²⁷Th-conjugate therapy in mice
Linda N Broer, Daan G Knapen, Frans Valentijn Suurs, Ingrid Moen, Danique Giesen, Stijn J H Waaijer, Baard Indrevoll, Christine Ellingsen, Alexander Kristian, Alan S Cuthbertson, Derk-Jan A de Groot, Patricia E Cole, Elisabeth G.E. de Vries, Urs B Hagemann and Marjolijn N Lub - de Hooge

Journal of Nuclear Medicine April 14, 2022, jnumed.121.263079; DOI: https://doi.org/10.2967/jnumed.121.263079
You have access
A pipeline for automated voxel dosimetry: application in patients with multi-SPECT/CT imaging following ¹⁷⁷Lu peptide receptor radionuclide therapy
Yuni K. Dewaraja, David M Mirando, Avery Peterson, Jeremy Niedbala, John D Millet, Justin K Mikell, Kirk Frey, Ka Kit Wong, Scott Wilderman and Aaron S Nelson

Journal of Nuclear Medicine April 14, 2022, jnumed.121.263738; DOI: https://doi.org/10.2967/jnumed.121.263738
You have access
Heterogeneity of SSTR2 expression assessed by ⁶⁸Ga-DOTATOC PET/CT using coefficient of variation in patients with neuroendocrine tumors
Rosa Fonti, Mariarosaria Panico, Sara Pellegrino, Alessandro Pulcrano, Luisa Alessia Vastarella, Armin Hakkak, Mario Giuliano, Giovannella Palmieri, Sabino De Placido and Silvana Del Vecchio

Journal of Nuclear Medicine March 10, 2022, jnumed.121.262928; DOI: https://doi.org/10.2967/jnumed.121.262928
Open Access
mCRPC patients receiving ²²⁵Ac-PSMA-617 therapy in post androgen deprivation therapy setting: Response to treatment and survival analysis
Mike Sathekge, Frank Bruchertseifer, Mariza Vorster, Ismaheel Lawal, Otto Knoesen, Johncy Mahapane, Cindy Davis, Amanda Mdlophane, Alex Maes, Kgomotso Mokoala, Kgomotso Mathabe, Christophe Van de Wiele and Alfred Morgenstern

Journal of Nuclear Medicine February 17, 2022, jnumed.121.263618; DOI: https://doi.org/10.2967/jnumed.121.263618
Open Access
Synthesis and Preclinical Evaluation of ¹⁷⁷Lu-labeled Radiohybrid PSMA Ligands (rhPSMAs) for Endoradiotherapy of Prostate Cancer
Alexander Wurzer, Jan-Philip Kunert, Sebastian Fischer, Veronika Felber, Roswitha Beck, Francesco De Rose, Calogero D'Alessandria, Wolfgang Andreas Weber and Hans-Jürgen Wester

Journal of Nuclear Medicine January 27, 2022, jnumed.121.263371; DOI: https://doi.org/10.2967/jnumed.121.263371
You have access
Targeted Alpha-Emitter Therapy With ²¹²Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Human, Dose-Escalation Clinical Trial
Ebrahim S Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, Julien Torgue, Jason Hurt, Afshin Shafie and Rodolfo Núñez

Journal of Nuclear Medicine January 6, 2022, jnumed.121.263230; DOI: https://doi.org/10.2967/jnumed.121.263230

Main menu

User menu

Search

More articles from Theranostics

Pages